Literature DB >> 19056239

Circulating visfatin in chronic obstructive pulmonary disease.

Xiaojing Liu1, Yulin Ji, Jian Chen, Shuangqing Li, Fengming Luo.   

Abstract

OBJECTIVE: Malnutrition and continuous systemic inflammation occur frequently in patients with chronic obstructive pulmonary disease (COPD). Visfatin is a new adipokine, which increases in some inflammatory diseases. Its plasma level and relation with nutritional status and inflammation in COPD remain unknown. This study compared visfatin levels, nutritional status, and inflammation markers in patients with COPD and healthy controls.
METHODS: Plasma visfatin, tumor necrosis factor-alpha (TNF-alpha) and C-reactive protein (CRP) were measured in 35 patients with COPD and 28 healthy controls. Body composition was assessed with bioelectrical impedance analysis.
RESULTS: Significantly lower body mass index and percentage of body fat were observed in patients with COPD compared with control subjects. The levels of plasma visfatin were higher in the COPD group compared with healthy controls (2.07 +/- 0.18 versus 1.88 +/- 0.15 ng/mL, P < 0.001). Levels of TNF-alpha and CRP were also significantly higher in patients with COPD compared with controls. Plasma CRP and TNF-alpha were positively correlated with visfatin in the COPD group. No significant correlations were found between visfatin and body mass index or percentage of body fat in both groups.
CONCLUSION: Plasma visfatin levels increased in patients with COPD. This increased adipocytokine was significantly correlated with TNF-alpha and CRP. Visfatin may be a new proinflammatory adipocytokine in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19056239     DOI: 10.1016/j.nut.2008.09.008

Source DB:  PubMed          Journal:  Nutrition        ISSN: 0899-9007            Impact factor:   4.008


  12 in total

1.  Resistin and visfatin: are they valuable enough to be the differential diagnosis in familial Mediterranean fever with acute appendicitis?

Authors:  Bunyamin Kisacik; Mehmet Fatih Erol; Gulsen Yilmaz; Fatma Meric Yilmaz; Yuksel Maras; Umut Kalyoncu; Omer Karadag; Sedat Kiraz; Ihsan Ertenli; Meral Calguneri
Journal:  Clin Rheumatol       Date:  2011-07-07       Impact factor: 2.980

2.  Inhibition of nicotinamide phosphoribosyltransferase reduces neutrophil-mediated injury in myocardial infarction.

Authors:  Fabrizio Montecucco; Inga Bauer; Vincent Braunersreuther; Santina Bruzzone; Alexander Akhmedov; Thomas F Lüscher; Timo Speer; Alessandro Poggi; Elena Mannino; Graziano Pelli; Katia Galan; Maria Bertolotto; Sébastien Lenglet; Anna Garuti; Christophe Montessuit; René Lerch; Corinne Pellieux; Nicolas Vuilleumier; Franco Dallegri; Jacqueline Mage; Carlos Sebastian; Raul Mostoslavsky; Angèle Gayet-Ageron; Franco Patrone; François Mach; Alessio Nencioni
Journal:  Antioxid Redox Signal       Date:  2012-05-14       Impact factor: 8.401

Review 3.  Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.

Authors:  Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-04-20       Impact factor: 4.711

4.  The impact of low subcutaneous fat in patients with nontuberculous mycobacterial lung disease.

Authors:  Seok Jeong Lee; Yon Ju Ryu; Jin Hwa Lee; Jung Hyun Chang; Sung Shine Shim
Journal:  Lung       Date:  2014-02-19       Impact factor: 2.584

5.  Visfatin levels in patients with severe pneumonia.

Authors:  Xie Juan; Yi-Ming Lu; Jin-Dong Shi; Xing-Qi Deng; Wei Long
Journal:  World J Emerg Med       Date:  2011

6.  Visfatin Regulates Inflammatory Mediators in Mouse Intestinal Mucosa Through Toll-Like Receptors Signaling Under Lipopolysaccharide Stress.

Authors:  Xin Xin Pang; Abdur Rahman Ansari; Wen Jie Yang; Xiao Yu Niu; Ling Dong; Hui Zhen Li; Fen Liang Xu; Zhe Wei Zhang; Ke Xiao; Song Hui
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2021-04-15       Impact factor: 4.291

7.  Serum levels of visfatin, sirtuin-1, and interleukin-6 in stable and acute exacerbation of chronic obstructive pulmonary disease.

Authors:  Hassan Ghobadi; Sara Mokhtari; Mohammad Reza Aslani
Journal:  J Res Med Sci       Date:  2021-02-27       Impact factor: 1.852

8.  Metabolic phenotype and adipose tissue inflammation in patients with chronic obstructive pulmonary disease.

Authors:  Peter Skyba; Jozef Ukropec; Pavol Pobeha; Barbara Ukropcova; Pavol Joppa; Timea Kurdiova; Katarina Stroffekova; Miroslav Brusik; Iwar Klimes; Ivan Tkac; Daniela Gasperikova; Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-12-21       Impact factor: 4.711

Review 9.  Inflammatory Markers and the Risk of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.

Authors:  Bin Su; Tiansheng Liu; Haojun Fan; Feng Chen; Hui Ding; Zhouwei Wu; Hongwu Wang; Shike Hou
Journal:  PLoS One       Date:  2016-04-22       Impact factor: 3.240

10.  Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease.

Authors:  Sirpa Leivo-Korpela; Lauri Lehtimäki; Mari Hämälainen; Katriina Vuolteenaho; Lea Kööbi; Ritva Järvenpää; Hannu Kankaanranta; Seppo Saarelainen; Eeva Moilanen
Journal:  Mediators Inflamm       Date:  2014-05-06       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.